Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Parasite Ubiquinol Oxidation Site Inhibitor
ELQ-121 is a potent inhibitor targeting the ubiquinol oxidation site in parasites. It exhibits remarkable antimalarial activity, with an IC50 of 0.05 nM against both chloroquine-sensitive and multidrug-resistant strains of P. falciparum in vitro. Additionally, ELQ-121 demonstrates high efficacy against T. gondii and N. caninum, with IC50 values below 1 nM, and suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM, accompanied by mitochondrial disruption. Furthermore, the compound can be formulated as a polyethylene glycol carbonate ester prodrug, showing in vivo efficacy against P. yoelii in mice, making it a valuable tool for antimalarial research. -
Parasite Inhibitor
BRD5018 is a selective antimalarial agent that targets Plasmodium parasites. This compound functions as a click chemistry reagent, featuring an alkyne group that participates in copper-catalyzed azide-alkyne cycloaddition (CuAAc). Its ability to facilitate this reaction expands its utility in chemical biology applications, particularly in the development of novel therapeutic strategies against malaria. -
Parasite Inhibitor
Antimalarial agent 2 is a novel compound that targets Plasmodium parasites, displaying a rapid in vitro killing profile. This reagent demonstrates potent antiparasitic activity, making it a valuable tool for research into malaria treatment and the development of effective antimalarial therapies. Its oral efficacy indicates potential for further exploration in therapeutic applications against malaria. -
Parasite Inhibitor
Carbarsone, or p-ureidobenzenearsonic acid, primarily functions as a parasite inhibitor with notable efficacy as an amebicide. Historically utilized in human and veterinary medicine, it has been incorporated into poultry and swine feed to mitigate conditions such as blackhead in turkeys, often in conjunction with antibiotics. Its relatively low acute toxicity has prompted research into its safety as a food additive, with studies indicating minimal carcinogenic risk under chronic ingestion, similar to other arsanilic acid derivatives. Carbarsone is metabolized to arsanilic acid, which has been investigated in high-dose studies in canine models. -
Parasite Inhibitor
MMV666810 is a potent parasite inhibitor that targets asexual stages of parasites, exhibiting an IC50 of 5.94 nM. Notably, it demonstrates a 3.3-fold selectivity for late-stage gametocytes over earlier stages, with IC50 values of 179 ± 8 nM for late-stage and 603 ± 88 nM for early-stage gametocytes. This compound is valuable for research applications focused on antimalarial drug development and understanding gametocyte biology. -
Parasite Inhibitor
3-ANOT is a metabolite of Dinitolmide, functioning primarily as a parasite inhibitor. It demonstrates significant efficacy against coccidia, making it essential for research into antiparasitic mechanisms. 3-ANOT is applicable in studies focused on the prevention and treatment of parasitic infections in livestock, especially in poultry. -
Parasite Inhibitor
IWY357 is a potent inhibitor of Plasmodium falciparum, specifically targeting the blood stage of the parasite. This compound exhibits significant efficacy in disrupting the life cycle of the parasite, making it a valuable tool for researchers investigating malaria infection mechanisms and developing therapeutic strategies. Its long-acting properties can contribute to the understanding of parasite biology and assist in the design of novel anti-malarial drugs. -
Nematode Growth Inhibitor
5-(4-Methoxyphenyl)oxazole is a nematode growth inhibitor that targets Caenorhabditis elegans, effectively interfering with hatching and growth processes. This compound, derived from fungal culture broth, exhibits potential in studying nematode biology and assessing the efficacy of nematicidal agents. Its application in research provides valuable insights into nematode management and development. -
Parasite Inhibitor
Nopol is a quinoline derivative that acts as a potent inhibitor of the asexual blood stage of Plasmodium falciparum. Its structural variations result in differing biological activities against various Plasmodium strains, with certain derivatives exhibiting submicromolar EC50 values for specific strains. This compound is valuable for research focused on malaria treatment and the development of antimalarial agents. -
Parasite Inhibitor
Phebestin is a compound that exhibits potent antimalarial activity by inhibiting the growth of Plasmodium spp. It demonstrates significant efficacy in both in vitro and in vivo studies. Additionally, Phebestin interacts with key enzymes associated with the Plasmodium life cycle, making it a valuable tool for research in parasitology and the development of novel antimalarial therapies. -
Parasite Inhibitor
M&B 5124 is a potent inhibitor targeting Schistosoma mansoni, a pathogenic trematode responsible for schistosomiasis. This compound demonstrates significant antiparasitic activity in murine models, making it a valuable tool for research into therapeutic strategies against schistosomiasis. Its efficacy positions it as a candidate for further studies aimed at understanding parasitic infections and developing new treatment options. -
FREP1 Inhibitor
P-orlandin is a specific inhibitor of FREP1, a protein that mediates the binding of Plasmodium gametocytes and ookinetes. This fungal metabolite demonstrates potent activity in blocking Plasmodium falciparum infections in mosquito vectors, making it a valuable tool for research in malaria transmission and vector control studies. Its unique mode of action offers insights into potential strategies for disrupting the lifecycle of malaria parasites. -
Parasite Inhibitor
Melarsonyl dipotassium is a potent anthelmintic agent that targets various parasitic organisms. By interfering with metabolic processes in parasites, it exhibits significant inhibitory activity, making it valuable for research in parasitology and drug development. This compound is particularly relevant in studying the mechanisms of anthelmintic resistance and developing novel therapeutic strategies against parasitic infections. -
Parasite Inhibitor
trans-Cinnamic anhydride is a parasite inhibitor with a primary target of Plasmodium falciparum. This compound, isolated from Cinnamomum zeylanicum, demonstrates moderate antimalarial activity. It is utilized in pharmacological studies aimed at developing therapeutic agents against parasitic infections. -
Parasite Inhibitor
Epsiprantel is a potent anti-Echinococcus compound that functions as a parasite inhibitor, effectively inducing the death of protoscolex, larvae, and adult stages of the parasite in vitro. In vivo studies demonstrate its higher efficacy against mature worms compared to larvae, making it a valuable tool for research into Echinococcus infections and potential therapeutic strategies. Epsiprantel is characterized by its safety profile, showing no adverse side effects in tested models. -
Parasite Inhibitor
6-O-Methacrylate is a trilobolide derivative derived from the leaves of Wedelia trilobata, functioning primarily as a parasite inhibitor. It exhibits significant antimalarial activity with an IC50 of 8.9 μg/mL against the Plasmodium falciparum parasite. Additionally, 6-O-Methacrylate demonstrates antiviral properties by inhibiting the tobacco mosaic virus (TMV). This compound is valuable for research in parasitology and virology. -
Parasite Inhibitor
Cyclobendazole is a benzimidazole derivative targeting protozoan parasites. It demonstrates potent in vitro activity against Trichomonas vaginalis and Giardia lamblia, with IC50 values of 1.1 μg/mL and 0.047 μg/mL, respectively. This compound is useful in research applications focused on combating protozoal infections and studying their biological pathways. -
Parasite Inhibitor
Fenbendazole sulfone is a benzimidazole anthelmintic agent that acts as a parasite inhibitor. It is a minor metabolite of fenbendazole, demonstrating significant activity against various helminths. This compound is primarily utilized in research focused on parasitic infections and anthelmintic drug development. -
Parasite Inhibitor
Anti-infective agent 9 is an inhibitor of Plasmodium falciparum, exhibiting an IC50 of 600 nM, which targets metabolic pathways by downregulating pyruvate levels and interfering with the TCA cycle. This compound demonstrates favorable metabolic stability and low toxicity in human liver cells, making it a viable candidate for further research into antimalarial therapies. Additionally, studies suggest that its mechanism of action may involve pathways beyond 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), highlighting its potential as a multifaceted therapeutic agent in combating malaria. -
Parasite Inhibitor
Lettowienolide is a geranylbenzoquinonoid that targets the Plasmodium falciparum malaria parasite. It demonstrates mild in vitro inhibitory activity, with an IC50 of approximately 20 μg/mL. This compound is relevant for research applications focusing on malaria treatment and the exploration of new therapeutic agents against parasitic infections. -
Parasite Inhibitor
Amabiline is a natural compound derived from specific plant sources, exhibiting potent activity as a parasite inhibitor. It demonstrates notable biological effects that make it valuable for research involving parasitic infections. Amabiline’s unique pharmacological properties may also provide insights into potential therapeutic applications, while its safety profile warrants consideration in various experimental contexts. -
Parasite Inhibitor
Antimalarial Agent 3 is a potent parasite inhibitor that exhibits nanomolar antiplasmodial activity, with an IC50 value of 0.035 μM. This compound demonstrates a high selectivity index, indicating minimal toxicity to mammalian cells. Its effectiveness makes it a valuable tool for research focused on developing antimalarial therapies and understanding parasite biology. -
Parasite Inhibitor
LAPTc-IN-1 is a competitive inhibitor of acidic M17 leucinopeptidase (LAPTc), exhibiting a Ki value of 0.27 μM. This compound demonstrates potent antagonistic activity against the parasite Trypanosoma cruzi, making it a valuable tool for research into parasitic infections. Its specificity towards LAPTc positions it as a potential candidate for the development of therapeutic strategies targeting Chagas disease and other related conditions. -
Parasite Inhibitor
Linearolactone is a compound that exhibits potent anti-Giardia activity, primarily targeting Giardia trophozoites. It induces necrotic cell death in these parasites, which can be attributed to its interaction with a predicted target protein. This compound is valuable for research applications focused on parasitic infections and the development of new therapeutic strategies against Giardia. -
Parasite Inhibitor
Anti-parasitic agent 3 is a potent inhibitor targeting resistant parasites, exhibiting significant anti-parasitic activity. This compound is essential for research applications focused on parasitic infections and the development of effective treatments. Its mechanism of action provides valuable insights into overcoming resistance in various parasitic species. -
Parasite Inhibitor
SSJ-183 is a parasite inhibitor with notable antimalarial activity. It functions by modulating both the efficacy and pharmacokinetic properties relevant to antimalarial treatment. Studies have demonstrated its potential in antimalarial research, positioning SSJ-183 as a significant candidate for the development of new combination therapies targeting malaria. -
Parasite Inhibitor
GSK932121 is a selective antimalarial agent that targets the electron transport chain of Plasmodium falciparum by inhibiting cytochrome bc1 (complex III). This compound disrupts the parasite's metabolic processes, demonstrating significant activity against malaria. Due to its efficient five-step synthesis process, GSK932121 can be produced at kilogram scale, making it suitable for extensive clinical research applications. -
Parasite Inhibitor
MMV674850 is a potent inhibitor targeting asexual stage parasites, exhibiting IC50 values of 2.7 and 4.5 nM. This compound preferentially affects early-stage gametocytes, with an IC50 of 4.5 ± 3.6 nM, while late-stage gametocytes display an IC50 of 28.7 ± 0.2 nM. MMV674850 serves as a valuable tool for research focused on malaria and parasite biology, particularly in investigating gametocyte development and inhibition strategies. -
Parasite Inhibitor
PfPKG-IN-1 is an imidazole-based inhibitor targeting Plasmodium falciparum cGMP-dependent protein kinase (PfPKG). This compound exhibits significant biological activity by interfering with the function of PfPKG, an essential enzyme in the life cycle of the malaria parasite. PfPKG-IN-1 is utilized in research applications aimed at developing effective antimalarial therapies and understanding the molecular mechanisms of parasite survival and replication. -
Parasite Inhibitor
6-Benzylthioinosine acts as a potent inhibitor of parasite growth, demonstrating significant antileukemic activity by enhancing cytotoxic effects against acute myeloid leukemia cells. It operates by modulating cellular metabolism and influencing signaling pathways, particularly when used in combination with metformin. This compound is valuable for research applications focused on leukemia treatment and understanding metabolic regulation in cancer. -
Parasite Inhibitor
Antileishmanial agent-2 is a potent inhibitor targeting Leishmania parasites, demonstrating submicromolar antileishmanial activity with an IC50 value of 0.29 μM. This compound exhibits a high selectivity index, indicating minimal toxicity to mammalian cells. It is suitable for research applications focused on the development of therapies for leishmaniasis and related parasitic infections. -
Parasite Inhibitor
(+)-Isopulegol functions primarily as a parasite inhibitor, derived from the terpenoid constituents of Mentha canadensis L. It exhibits phagostimulatory effects on adult pests, particularly S. granarius and T. confusum, acting as a feeding attractant for adult T. confusum and larvae of T. granarium. This compound is valuable for research applications in pest control and management strategies targeting stored product insects. -
Parasite Inhibitor
SLU-10906 is a potent inhibitor targeting the protozoan parasite Cryptosporidium. Demonstrating significant efficacy in a cell-based infection model with an EC50 of 0.19 μM, SLU-10906 is non-cytotoxic, making it a valuable tool for investigating cryptosporidiosis. Its oral bioavailability further enhances its potential for preclinical studies and therapeutic exploration. -
Parasite Inhibitor
Carbonic anhydrase inhibitor 27 is a targeted antitrypanosomal agent that inhibits carbonic anhydrase activity, impacting parasite viability. This compound effectively reduces parasitic load in the bloodstream and enhances the survival rate of infected murine models. It is valuable for research applications focused on the treatment of parasitic infections such as Trypanosomiasis. -
Parasite Inhibitor
MMV665852 is an antischistosomal agent that targets Schistosoma mansoni, inhibiting worm viability in vitro. This compound has demonstrated efficacy in reducing worm burden in murine models of schistosomiasis, making it a valuable tool for research in parasitic disease treatment and prevention. -
Inhibitor of Parasite Motility and Invasion
TachypleginA-2 is a small-molecule inhibitor that targets parasite motility and invasion. It effectively induces a mobility shift in TgMLC1, an essential light chain involved in cellular movement. This compound is useful for research investigating the mechanisms of parasitic behavior and the development of potential therapeutic strategies against parasitic infections. -
Parasite Inhibitor
Bitipazone is a potent cysteine ester derivative that serves as an effective anticoccidial agent. It demonstrates significant efficacy against coccidian parasites in animal models, including rabbits and turkeys, with good tolerability observed at concentrations below 90 ppm in feed. Pharmacokinetic studies indicate that Bitipazone is slowly eliminated from the blood and organs, making it a valuable compound for research in parasitology and veterinary medicine. -
Parasite Inhibitor
AB 3217-B is a parasite inhibitor that targets mite species with potent anti-mite activity. This compound demonstrates efficacy in disrupting the life cycle of parasites, making it valuable for research related to pest control and parasitology. Its ability to inhibit mite proliferation positions it as a potential candidate for further studies aimed at developing effective treatments against parasitic infestations. -
Parasite Inhibitor
Anti-Trypanosoma cruzi agent-5 is a potent inhibitor of Trypanosoma cruzi, the causative agent of Chagas disease. This compound demonstrates significant antiparasitic activity, inhibiting the proliferation of the parasite in vitro. It is suitable for research applications investigating the mechanisms of Chagas disease and potential therapeutic strategies. -
Parasite Inhibitor
RS 49676 is an N-substituted imidazole compound that acts as a potent inhibitor against endogenous amoebae, displaying an ED50 of less than 0.1 ng/mL. It demonstrates significant biological activity in vivo, notably prolonging the average survival time of mice infected with Trypanosoma cruzi to over 11 weeks when administered at a dose of 100 mg/kg per day via subcutaneous injection. This compound is valuable for research applications involving parasitic infections and host-pathogen interactions. -
Parasite Tyrosyl-tRNA Synthetase Inhibitor
ML471 is an orally active inhibitor of parasite tyrosyl-tRNA synthetase (PfTyrRS), which is essential for protein synthesis in Plasmodium species. This compound exhibits potent activity against malaria by selectively targeting PfTyrRS, providing valuable insights into the treatment of malaria infections. It is a useful tool for researchers investigating novel antimalarial strategies and exploring the role of tRNA synthetases in parasitic biology. -
Parasite Inhibitor
(Rac)-ACT-451840 is a parasite inhibitor with significant antimalarial properties. It demonstrates effective antimalarial activity against P. berghei-infected mice, achieving an ED90 of 13 mg/kg and showing inhibitory effects at higher doses. In humanized immunodeficient mouse models infected with P. falciparum, the compound has an ED90 of 3.7 mg/kg. (Rac)-ACT-451840 is structurally similar to artemisinin and offers a rapid onset of action, although it necessitates repeated high dosing for optimal efficacy. -
Parasite Inhibitor
WRR-483 is an irreversible cysteine protease inhibitor targeting cruzain, demonstrating potent trypanocidal activity against Trypanosoma cruzi. This compound effectively inhibits the proliferation of the parasite in cell culture and shows significant efficacy in eradicating parasitic infection in acute Chagas disease mouse models. Its pH-dependent high affinity makes WRR-483 a promising candidate for research applications focused on combating Chagas disease. -
Reverse Transcriptase Inhibitor
5'-Azido-5'-deoxythymidine is a nucleoside analogue that functions as an inhibitor of reverse transcriptase. By mimicking natural nucleosides, it integrates into viral DNA during replication, thereby terminating chain elongation and effectively inhibiting viral propagation. This compound is valuable for research into retroviral infections, including AIDS, contributing to the understanding and treatment of these diseases. -
reverse transcriptase inhibitor
Depulfavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates exceptional antiviral activity with an IC50 of 1.1 nM against wild-type HIV-1 and maintains effectiveness (IC50 < 100 nM) against 92% of various NNRTI-resistant clinical isolates. This compound is valuable for research into HIV resistance mechanisms and the development of novel antiviral therapies. -
AMV Reverse Transcriptase Inhibitor
Limocrocin is an inhibitor of avian myeloid leukemia virus (AMV) reverse transcriptase. This compound, derived from Streptomyces limosus, exhibits significant inhibitory activity independent of variations in template-primer concentration, substrate, or carrier protein levels. However, its efficacy diminishes with increasing concentrations of AMV reverse transcriptase. Limocrocin serves as a valuable tool for research in antiviral treatment development. -
Non-nucleoside Reverse Transcriptase Inhibitor
(R)-Efavirenz is a non-nucleoside reverse transcriptase inhibitor that acts through non-competitive inhibition of the viral enzyme. It is selectively metabolized by CYP2B6 to form 8-hydroxyefavirenz, which highlights its potential as a probe for studying the CYP2B6 active site and its catalytic mechanisms. This compound serves as a valuable tool in the research of antiviral therapeutics and the pharmacokinetics of HIV treatment. -
Reverse Transcriptase Inhibitor
Trovirdine hydrochloride is an HIV reverse transcriptase inhibitor, acting as a non-nucleoside inhibitor (NNI) of the enzyme. It demonstrates significant biological activity against HIV replication, effectively achieving inhibition at nanomolar concentrations without cytotoxic effects in infected peripheral blood mononuclear cells. This compound serves as a valuable tool for research applications focused on understanding HIV therapeutics and developing more potent derivatives for enhancing antiviral strategies. -
Reverse Transcriptase Inhibitor
Mniopetal E is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by interfering with the reverse transcription process, making it valuable for research in viral replication studies and the development of antiviral therapies. Its selective inhibition of reverse transcriptase may also provide insights into nucleic acid synthesis mechanisms in various biological systems. -
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies.
